PRG2 Knockout cell line (Jurkat, Clone E6-1)
Red cotton OmniCell bank
Online inquireOverview
Ubigene gene knockout cell lines mediated by optimized CRISPR-Cas9 technology provide reliable in vitro models for investigating gene function, signaling pathways, disease mechanisms, and therapeutic targets.
A human T-cell line originating from the peripheral blood of a 14-year-old male with childhood T-cell acute lymphoblastic leukemia, Jurkat, Clone E6-1 represents a clone of the Jurkat-FHCRC derivative. The line is classified as a T-cell lymphoblast and has been characterized with genomic and proteomic studies. It is associated with precursor T-cell acute lymphoblastic leukemia and retains the biological characteristics of its leukemia-derived origin.
Before delivery, each clone is authenticated by STR, tested for sterility and mycoplasma, and genotype‑verified by two‑round PCR‑sequencing. Comprehensive QC data accompany every shipment to support reproducible research.
Product Overview
Key Advantages
Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.
Quality Control Specifications
Knockout Region:
Reference Transcript: PLCG1-223
Validation Method: PCR amplification+Sanger sequencing
Download STR ReportIntended use
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use
Unpacking and Storage Instructions
Handling procedure
References
FAQ
Related Popular Products
Contact Us
Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?
